OVHIPEC-1
Washing the abdomen with heated chemotherapy during interval surgery extended survival by about a year.
OS 45.7 vs 33.9 months (HR 0.67; NEJM 2018), confirmed at 10-year follow-up (Lancet Oncology 2023) with no increase in serious complications. Uptake remains uneven; OVHIPEC-2 tests HIPEC at primary surgery.
Setting
Stage III ovarian cancer at interval cytoreductive surgery after neoadjuvant chemotherapy: HIPEC with cisplatin vs surgery alone
Phase
Phase 3
Sponsor
Netherlands Cancer Institute
Registry
Headline result
OS 45.7 vs 33.9 months (HR 0.67).
Reported
2018
Enrolled
245
Replication
Korean trial (Lim et al., JAMA Surgery 2022) showed benefit in the interval-surgery subgroup; OVHIPEC-2 (primary surgery) ongoing.
In plain words
What these results mean for people, not percentages
Overall survivalsurvival endpoint
- Median 45.7 vs 33.9 months with Surgery + HIPEC compared with Surgery alone; about 11.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 33 percent lower chance of the event at any given time (hazard ratio 0.67, likely range 0.48 to 0.94).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Stage III ovarian cancer at interval cytoreductive surgery after neoadjuvant chemotherapy: HIPEC with cisplatin vs surgery alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
245 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival | Surgery + HIPEC | 122 | 45.7 months | 0.67 (0.48–0.94) | — | link |
| Surgery alone | 123 | 33.9 months |
Replication
Korean trial (Lim et al., JAMA Surgery 2022) showed benefit in the interval-surgery subgroup; OVHIPEC-2 (primary surgery) ongoing.